Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $209
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on AbbVie and raised the price target from $196 to $209.
August 23, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has increased its price target for AbbVie from $196 to $209, maintaining an Overweight rating. This suggests confidence in AbbVie's future performance.
The increase in price target from $196 to $209 by Piper Sandler indicates a positive outlook on AbbVie's stock performance. Maintaining an Overweight rating suggests that the analyst expects AbbVie to outperform the market. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100